

Mi Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5223688/publications.pdf>

Version: 2024-02-01

22
papers

1,938
citations

516215

16
h-index

676716

22
g-index

22
all docs

22
docs citations

22
times ranked

2093
citing authors

#	ARTICLE	IF	CITATIONS
1	Synergistic H ₂ O ₂ self-supplying and NIR-responsive drug delivery nanoplatform for chemodynamic-photothermal-chemotherapy. <i>Colloids and Surfaces B: Biointerfaces</i> , 2022, 213, 112412.	2.5	8
2	Potency and Selectivity Optimization of Tryptophanolâ€Derived Oxazoloisoindolinones: Novel p53 Activators in Human Colorectal Cancer. <i>ChemMedChem</i> , 2021, 16, 250-258.	1.6	6
3	SD-91 as A Potent and Selective STAT3 Degradator Capable of Achieving Complete and Long-Lasting Tumor Regression. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 996-1004.	1.3	21
4	Discovery of EEDi-5273 as an Exceptionally Potent and Orally Efficacious EED Inhibitor Capable of Achieving Complete and Persistent Tumor Regression. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 14540-14556.	2.9	14
5	Discovery of Potent Small-Molecule Inhibitors of MLL Methyltransferase. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 1348-1352.	1.3	9
6	Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degradator of SHP2 Protein. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 7510-7528.	2.9	89
7	EEDi-5285: An Exceptionally Potent, Efficacious, and Orally Active Small-Molecule Inhibitor of Embryonic Ectoderm Development. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 7252-7267.	2.9	22
8	A Potent and Selective Small-Molecule Degradator of STAT3 Achieves Complete Tumor Regression In Vivo. <i>Cancer Cell</i> , 2019, 36, 498-511.e17.	7.7	364
9	Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degradator of STAT3 Protein. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 11280-11300.	2.9	133
10	Discovery of Highly Potent and Efficient PROTAC Degradators of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 11218-11231.	2.9	138
11	Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degradator of Estrogen Receptor (ER). <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1420-1442.	2.9	176
12	Changing the Apoptosis Pathway through Evolutionary Protein Design. <i>Journal of Molecular Biology</i> , 2019, 431, 825-841.	2.0	16
13	Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degradator of Androgen Receptor (AR) for the Treatment of Prostate Cancer. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 941-964.	2.9	269
14	Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degradator Capable of Achieving Complete and Durable Tumor Regression. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 448-466.	2.9	211
15	High-Affinity Peptidomimetic Inhibitors of the DCN1-UBC12 Proteinâ€Protein Interaction. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 1934-1950.	2.9	46
16	Design of the Firstâ€inâ€Class, Highly Potent Irreversible Inhibitor Targeting the Meninâ€MLL Proteinâ€Protein Interaction. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 1601-1605.	7.2	49
17	Design of the Firstâ€inâ€Class, Highly Potent Irreversible Inhibitor Targeting the Meninâ€MLL Proteinâ€Protein Interaction. <i>Angewandte Chemie</i> , 2018, 130, 1617-1621.	1.6	1
18	Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 6110-6120.	2.9	33

#	ARTICLE	IF	CITATIONS
19	Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degradar of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 6685-6704.	2.9	204
20	Preparation and characterization of 5-fluorouracil pH-sensitive niosome and its tumor-targeted evaluation: <i>in vitro</i> and <i>in vivo</i> . <i>Drug Development and Industrial Pharmacy</i> , 2012, 38, 1134-1141.	0.9	30
21	Uptake of Glycerol-2-Phosphate via the <i>ugp</i> -Encoded Transporter in <i>Escherichia coli</i> K-12. <i>Journal of Bacteriology</i> , 2009, 191, 4667-4670.	1.0	25
22	Formation of a Nickel ^{II} Methyl Species in Methyl-Coenzyme M Reductase, an Enzyme Catalyzing Methane Formation. <i>Journal of the American Chemical Society</i> , 2007, 129, 11028-11029.	6.6	74